| AASLD

Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient

Read more about Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient

Joel P. Wedd, Eric Nordstrom, Trevor Nydam, Janette Durham, Michael Zimmerman, Thor Johnson, W. Thomas Purcell, Scott W. Biggins – 12 October 2015 – Liver transplantation can provide definitive cure for patients with cirrhosis and hepatocellular carcinoma (HCC) when used appropriately. Advances in the management of HCC have allowed improved control of HCC while waiting for liver transplantation and new approaches to candidate selection particularly with regard to tumor burden and downstaging protocols.

Liver capsule: Age‐influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man

Read more about Liver capsule: Age‐influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man

Jean Publicover, Jillian M. Jespersen, Audra J. Johnson, Stephen L. Nishimura, Amanda Goodsell, Adil E. Wakil, Philip Rosenthal, Eric Pai, Lia Avanesyan, Stewart Cooper, Jody L. Baron – 12 October 2015

Prevalence of hepatitis delta infection in the United States: National Health and Nutrition Examination Survey, 1999‐2012

Read more about Prevalence of hepatitis delta infection in the United States: National Health and Nutrition Examination Survey, 1999‐2012

Basile Njei, Albert Do, Joseph K. Lim – 9 October 2015

Time to Abandon NASH?

Read more about Time to Abandon NASH?

Jean‐François Dufour – 9 October 2015

High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population?

Read more about High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population?

Aijaz Ahmed, Ryan B. Perumpail, Stephen A. Harrison – 9 October 2015

Integrin αvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis

Read more about Integrin αvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis

Zhen‐Wei Peng, Naoki Ikenaga, Susan B. Liu, Deanna Y. Sverdlov, Kahini A. Vaid, Richa Dixit, Paul H. Weinreb, Shelia Violette, Dean Sheppard, Detlef Schuppan, Yury Popov – 8 October 2015 – Integrin αvβ6 is rapidly up‐regulated on cells of epithelial lineage during tissue injury, where one of its primary functions is activation of latent transforming growth factor beta 1 (TGFβ1). In human liver cirrhosis, αvβ6 is overexpressed by cells comprising the ductular reaction, and its inhibition suppresses experimental biliary fibrosis in rodents.

Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and hepatic venous pressure gradient?)

Read more about Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and hepatic venous pressure gradient?)

Cristina Ripoll – 8 October 2015

NASH, from diagnosis to treatment: Where do we stand?

Read more about NASH, from diagnosis to treatment: Where do we stand?

Stephen A. Harrison – 8 October 2015

Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and hepatic venous pressure gradient?)

Read more about Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and hepatic venous pressure gradient?)